de Jong Andy, Woods Kate, Van Gestel Lise, Suresh Mohanraj, Porteous Matthew
Department of Orthopaedic Surgery, West Suffolk Hospital, Bury St. Edmunds, Suffolk, UK.
Acta Orthop Belg. 2013 Oct;79(5):578-86.
Assessment and treatment of osteoporosis are recommended following hip fracture. Osteoporosis treatment assumes an adequate calcium intake and a normal vitamin D plasma level. The authors conducted a study in three phases. Phase I: circulating 25-hydroxyvitamin D levels were retrospectively recorded from in the case records of 381 consecutive patients with 387 hip fractures, between March 2010 and September 2011. Only 27 patients had sufficient (> 75 nmol/L) circulating vitamin D, and of these 22 were taking vitamin D supplements. The remainder, 354 patients, had abnormally low vitamin D levels, with a mean value of 26.4 nmol/L. These findings confirmed literature data, and gave rise to the prospective Phase II (October 2011): 14 consecutive patients with a hip fracture received rapid substitution therapy with 50,000 IU cholecalciferol (vitamin D3) daily for 3 days. Patients with corrected calcium level (calcium level based on the serum albumin level) > 2.60 mmol/L were excluded from phase II (and phase III), in order to avoid hypercalcemia. Substitution resulted in an increase in vitamin D plasma levels from +/- 29.6 nmol/L to +/- 81.4 nmol/L (p < 0.0001), after +/- 14 days. However, vitamin D level remained below the desired threshold of 75 nmol/L in 29%. Therefore it was decided to increase the treatment period from 3 days to 7 days in the next 54 patients with a hip fracture in a prospective phase III (October 2011-January 2012). This time rapid substitution resulted in an increase from +/-31.4 nmol/L to +/-131.1 nmol/L (p < 0.0001), after +/- 16 days, and 100% of treated patients achieved plasma levels above the desired threshold of 75 nmol/L.
virtually all patients with a hip fracture have low vitamin D plasma levels; substitution with 50,000 IU oral cholecalciferol daily for 7 days increases vitamin D plasma levels rapidly, safely and consistently.
髋部骨折后建议进行骨质疏松症的评估和治疗。骨质疏松症治疗需保证充足的钙摄入量以及正常的维生素D血浆水平。作者进行了一项分三个阶段的研究。第一阶段:回顾性记录了2010年3月至2011年9月期间381例连续发生387例髋部骨折患者病历中的循环25-羟维生素D水平。只有27例患者循环维生素D充足(>75nmol/L),其中22例正在服用维生素D补充剂。其余354例患者维生素D水平异常低,平均值为26.4nmol/L。这些发现证实了文献数据,并由此开展了前瞻性的第二阶段研究(2011年10月):14例连续的髋部骨折患者接受了快速替代疗法,每天服用50,000IU胆钙化醇(维生素D3),持续3天。校正钙水平(基于血清白蛋白水平的钙水平)>2.60mmol/L的患者被排除在第二阶段(和第三阶段)之外,以避免高钙血症。替代治疗后约14天,维生素D血浆水平从±29.6nmol/L升至±81.4nmol/L(p<0.0001)。然而,29%的患者维生素D水平仍低于75nmol/L的理想阈值。因此,在前瞻性的第三阶段研究(2011年10月至2012年1月)中,决定将接下来54例髋部骨折患者的治疗期从3天延长至7天。这次快速替代治疗后约16天,维生素D水平从±31.4nmol/L升至±131.1nmol/L(p<0.0001),并且100%接受治疗的患者血浆水平达到了75nmol/L的理想阈值以上。
几乎所有髋部骨折患者的维生素D血浆水平都较低;每天口服50,000IU胆钙化醇,持续7天进行替代治疗可快速、安全且持续地提高维生素D血浆水平。